Page 5 - Phasei Ii News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Phasei ii. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Phasei Ii Today - Breaking & Trending Today
Introduction to eLAS® Clinical Ink has developed a unique offering the electronic Lupus Assessment Suite (eLAS ®) to address fundamental challenges impacting systemic lupus erythematosus (SLE) studies and the integrity of the study endpoints. eLAS is a therapeutic-specific application of Clinical Ink’s Lunexis™. Unlike other applications that simply offer stand-alone electronic versions of questionnaires, eLAS features a fully integrated suite of SLE disease assessment questionnaires, physical assessment, tender/swollen joint count, PGA, and summary forms. Latest content from Clinical Ink Content provided by Clinical Ink ....
A leader from Vocalis Health explains how health data can be culled from patient voice recordings to screen and monitor COVID-19 and other conditions. OSP: Could you please share the ‘elevator presentation’ description of Vocalis who you are, what you do, and what sets you apart? SH: Vocalis Health is an AI health tech company pioneering the development of vocal biomarkers – where health-related information is derived from analysis of people’s voice recordings – to screen, detect, monitor and predict health symptoms, conditions and diseases. In 2016, I co-founded Vocalis Health with Daniel Aronovich, chief technical officer of the company. While treating patients in the hospital, I realized that I was habitually listening to their voices to gauge the state of their health. ....
According to Noxopharm, a recent study shows combining its Veyonda drug and a radiopharmaceutical yields favorable results against prostate cancer. Noxopharm has released the most recent survival data from its LuPIN prostate cancer study. The company reports results show a median overall survival (mOS) of 19.7 months, higher than all other mOS results for existing prostate cancer treatments in their own registration studies. These findings reportedly support evidence that a combination of Veyonda (NOX66) and experimental radiopharmaceutical 177lutetium-PSMA-617 could be successful in the treatment of metastatic castrate-resistant prostate cancer (mCRPC). This could offer a patient with mCRPC a high chance of the cancer responding to treatment to the extent of obtaining a meaningful survival outcome. ....
The Verisense Pulse+ can measure heart rate, oxygen saturation, emotional responses, and activity and sleep levels of at-home clinical trial participants. Shimmer Research has announced its Verisense Pulse+ sensor for use with its Verisense wearable sensor platform. The device is designed to offer photoplethysmogram (PPG), galvanic skin response (GSR), and inertial measurement unit (IMU). According to the company, the PPG sensor monitors heart rate by using light absorption to measure changes in capillary blood volume. The GSR sensor measures changes in sweat-gland activity; this can be used to gauge the patient’s level of psychological and emotional arousal, stress, and other responses; GSR typically is employed in psychological research and biofeedback, and it is started to be used in more clinical applications, such as epilepsy. ....